|
05.11.2024 10:02:28
|
EQS-Adhoc: PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer
|
EQS-Ad-hoc: PharmaSGP Holding SE / Key word(s): Personnel PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer Gräfelfing, November 05, 2024 – Peter Gerckens, who has been a member of the Management Board of PharmaSGP Holding SE as Chief Commercial Officer (CCO) since July 1, 2024, will take over the position of Chief Executive Officer (CEO) of the company on January 1, 2025. This was decided by the Supervisory Board today. Peter Gerckens succeeds Natalie Weigand in this position. She informed the Supervisory Board today that she has decided not to extend her contract, which expires at the end of the year. However, Natalie Weigand will remain associated with the company in an advisory role after her departure. * * * Contact PharmaSGP Holding SE End of Inside Information
05-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | PharmaSGP Holding SE |
| Lochhamer Schlag 1 | |
| 82166 Gräfelfing | |
| Germany | |
| E-mail: | ir@pharmasgp.com |
| Internet: | https://pharmasgp.com |
| ISIN: | DE000A2P4LJ5 |
| WKN: | A2P4LJ |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Tradegate Exchange |
| EQS News ID: | 2022283 |
| End of Announcement | EQS News Service |
|
|
2022283 05-Nov-2024 CET/CEST
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu PharmaSGPmehr Nachrichten
|
27.11.24 |
Ausblick: PharmaSGP legt Quartalsergebnis vor (finanzen.net) | |
|
25.11.24 |
EQS-DD: PharmaSGP Holding SE: FUTRUE GmbH, Kauf (EQS Group) | |
|
25.11.24 |
EQS-DD: PharmaSGP Holding SE: FUTRUE GmbH, buy (EQS Group) | |
|
14.11.24 |
EQS-News: PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised (EQS Group) | |
|
14.11.24 |
EQS-News: PharmaSGP mit kräftigem Umsatzwachstum in 9M 2024 – Erhöhung der Umsatzprognose für FY 2024 (EQS Group) | |
|
05.11.24 |
EQS-News: CEO-Wechsel bei der PharmaSGP Holding SE: Peter Gerckens folgt zum 01. Januar 2025 auf Natalie Weigand (EQS Group) | |
|
05.11.24 |
EQS-News: CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025 (EQS Group) | |
|
05.11.24 |
EQS-Adhoc: PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer (EQS Group) |
Analysen zu PharmaSGPmehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.